Hepatitis B Virus (HBV) Infection- Pipeline Insight, 2022

Hepatitis B Virus (HBV) Infection- Pipeline Insight, 2022

DelveInsight’s, “Hepatitis B Virus (HBV) Infection- Pipeline Insight, 2022” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hepatitis B Virus (HBV) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hepatitis B Virus (HBV) Infection: Understanding

Hepatitis B Virus (HBV) Infection: Overview

Hepatitis means inflammation of the liver. When the liver is inflamed or damaged, its function can be affected. Heavy alcohol use, toxins, some medications, and certain medical conditions can all cause hepatitis. However, hepatitis is often caused by a virus. In the United States, the most common hepatitis viruses are hepatitis A virus, hepatitis B virus, and hepatitis C virus. Hepatitis B is a liver infection caused by the hepatitis B virus. Some people with hepatitis B are sick for only a few weeks (known as “acute” infection), but for others, the disease progresses to a serious, lifelong illness known as chronic hepatitis B. Some people, especially those who get infected in adulthood, are able to clear the virus from their bodies without treatment. For other people, acute hepatitis B leads to life-long infection known as chronic hepatitis B. Over time, chronic hepatitis B can cause serious health problems, including liver damage, cirrhosis, liver cancer, and even death. Age plays a role in whether hepatitis B will become chronic. The younger a person is when infected with the hepatitis B virus, the greater the chance of developing chronic infection. About 9 in 10 infants who become infected go on to develop life-long, chronic infection. The risk goes down as a child gets older. About one in three children who get infected before age 6 will develop chronic hepatitis B. By contrast, almost all older children (those aged ≥6) and adults infected with the hepatitis B virus recover completely and do not develop chronic infection. Hepatitis B is spread when blood, semen, or other body fluid infected with the hepatitis B virus enters the body of someone who is not infected or has not been vaccinated. People can become infected with the virus from: Birth (spread from a mother who has hepatitis B to her baby during birth), sex with a partner who has hepatitis B, sharing needles, syringes, or drug preparation equipment and sharing items such as toothbrushes, razors, or medical equipment (like a glucose monitor) with a person who has hepatitis B. Many people with hepatitis B don’t know they are infected with the virus because they don’t feel or look sick. However, they can still spread the virus to others. The hepatitis B virus can survive outside the body for at least 7 days. During that time, the virus is still capable of causing infection. The best way to prevent hepatitis B is by getting vaccinated. The hepatitis B vaccine is safe and effective.

""Hepatitis B Virus (HBV) Infection- Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatitis B Virus (HBV) Infection pipeline landscape is provided which includes the disease overview and Hepatitis B Virus (HBV) Infection treatment guidelines. The assessment part of the report embraces, in depth Hepatitis B Virus (HBV) Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis B Virus (HBV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis B Virus (HBV) Infection R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis B Virus (HBV) Infection.

Hepatitis B Virus (HBV) Infection Emerging Drugs Chapters

This segment of the Hepatitis B Virus (HBV) Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hepatitis B Virus (HBV) Infection Emerging Drugs

• VIR 2218: Vir Biotechnology

VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.

• ABI H3733: Assembly Biosciences

ABI-H3733 (3733), is an investigational next-generation, highly potent core inhibitor. 3733 has demonstrated significantly increased potency against covalently closed circular DNA (cccDNA) formation and new virus production as compared to first-generation core inhibitors in preclinical studies. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Chronic Hepatitis B virus Infection.

• AB 729: Arbutus Biopharma

AB-729 is a subcutaneously-delivered RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. AB-729 targets hepatocytes using the novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology. AB-729 is currently being evaluated in a Phase 2a randomized, open-label, proof-of-concept clinical trial in combination with ongoing standard-of-care nucleos(t)ide analog therapy and short courses of Peg-IFNα-2a in 40 patients with chronic HBV infection.

Further product details are provided in the report……..

Hepatitis B Virus (HBV) Infection: Therapeutic Assessment

This segment of the report provides insights about the different Hepatitis B Virus (HBV) Infection drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hepatitis B Virus (HBV) Infection

There are approx. 80+ key companies which are developing the therapies for Hepatitis B Virus (HBV) Infection. The companies which have their Hepatitis B Virus (HBV) Infection drug candidates in the most advanced stage, i.e. phase II include, Arbutus Biopharma.

• Phases

DelveInsight’s report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Hepatitis B Virus (HBV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hepatitis B Virus (HBV) Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatitis B Virus (HBV) Infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatitis B Virus (HBV) Infection drugs.

Hepatitis B Virus (HBV) Infection Report Insights

• Hepatitis B Virus (HBV) Infection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hepatitis B Virus (HBV) Infection Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hepatitis B Virus (HBV) Infection drugs?
• How many Hepatitis B Virus (HBV) Infection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatitis B Virus (HBV) Infection?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hepatitis B Virus (HBV) Infection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hepatitis B Virus (HBV) Infection and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Assembly Biosciences
• Arbutus Biopharma
• Vir Biotechnology
• Nucorion Pharmaceuticals
• Gilead Sciences, Dong-A ST Co.
• Ltd., Assembly Biosciences
• Antios Therapeutics
• Ascletis Pharmaceuticals
• Shanghai HEP Pharmaceutical
• Romark Laboratories
• Qilu Pharmaceutical
• Golden Biotechnology
• Sunshine Lake Pharma
• Ascentage Pharma
• Vir Biotechnology
• GlaxoSmithKline
• Janssen Sciences
• Henlix
• Enyo Pharma
• Tasly Tianjin Biopharmaceutical
• Brii Biosciences
• Vaxine Pty Ltd
• Vaccitech limited
• Zhejiang Palo Alto Pharmaceuticals
• Suzhou Ribo Life Science
• PharmaEssentia
• Jiangsu HengRui Medicine
• Enanta Pharmaceuticals
• Chong Kun Dang Pharmaceutical
• Guangzhou Lupeng Pharmaceutical
• VenatoRx Pharmaceuticals
• Zhimeng Biopharma
• ISA Pharmaceuticals
• Dicerna Pharmaceuticals

Key Products

• VIR 2218
• ABI H3733
• AB 729
• NCO-48 Fumarate
• Pradefovir
• DA 2802
• VIR-2218
• Selgantolimod
• ATI-2173
• ASC42
• Hepalatide
• QL-007
• Antroquinonol
• HEC121120
• APG-1387
• GSK3228836
• JNJ-73763989
• JNJ-56136379
• Vonafexor
• T101
• BRII-179
• aVTP-300
• PA1010
• P1101
• HRS5091
• EDP-514
• CKD-388
• LP-128
• VNRX 9945
• ZM-H1505R
• ISA104
• RG6346
• HepTcell
• RO7049389


Please Note: It will take 7-10 business days to complete the report upon order confirmation.